NanoSyrinx appoints Jane Dancer to the Board as a new NED

NanoSyrinx is delighted to announce that Jane Dancer has agreed to join the Board and is bringing with her a wealth of business development and strategic knowledge for driving value from platform companies.

Jane is a well-known figure in the sector, having served as CBO at F-Star, Cambridge Antibody Technologies, as well as VP for Cellzome, and much more besides!

Jane will be instrumental in supporting the team as we build partnerships over the course of the next couple of years and the team is excited to be working together.

Full press release details can be found here:

Follow us on social media to stay up to date!


Read more news

NanoSyrinx featured by Spin-up Science on YouTube

Ben Miles at Spin-up Science took time recently to feature NanoSyrinx in their latest YouTube video. Follow the links below to learn how what NanoSyrinx is developing could, in Ben’s words, “change medicine forever”. You can also hear more from the discussion on the Scientist-to-CEO podcast Ben runs, which is available here: Spin up Science […]

Read more

NanoSyrinx named as winner of the 2022 AbbVie UK Golden Ticket programme

NanoSyrinx has been named as the winner of the 2022 AbbVie UK Golden Ticket accelerator programme. The 2022 AbbVie UK Golden Ticket is a competitive award, open to early-stage life sciences companies and biotech start-ups that are working to develop cutting-edge therapies or technology platforms. Under the programme, the company will benefit from: One year […]

Read more

NanoSyrinx featured in Drug Discovery News

NanoSyrinx’s CEO Joe Healey and academic co-founder Nick Waterfield have been interviewed by Drug Discovery News. In the article, they discuss the surprising origins and future potential of our nanosyringe technology. Read all about it here:

Read more